Navigation Links
Ranbaxy Receives Tentative Approval For Valsartan Tablets
Date:10/29/2007

To Benefit from 180 day exclusivity, at launch, due to its First To File

status

PRINCETON, N.J., Oct. 29 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valsartan Tablets, 40 mg, 80 mg, 160 mg and 320 mg. Total annual market sales for Valsartan Tablets were $1.3 billion (IMS - MAT: June 2007).

Valsartan is indicated for the treatment of hypertension alone or in combination with other anti-hypertensive agents. Valsartan is also indicated for the treatment of heart failure (NYHA class II-IV).

"We are pleased to receive tentative approval for Valsartan Tablets. We believe, we are first to file a substantially complete ANDA and will stand to gain from the 180 day exclusivity available to the first filer. These product formulations have been developed organically within Ranbaxy and will further expand our product portfolio of affordable generic alternatives," said Jim Meehan, Vice President of Sales and Distribution for RPI.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

CONTACTS: Charles M. Caprariello

Vice President, Corporate Communications

Ranbaxy Inc.

(609) 720-5615

Edwige Buteau

RF Binder Partners Inc.

(212) 994-7517

Anuj Baveja

RF Binder Partners Inc.

(212) 994-7552


'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. RANBAXY - enters anti-AIDS segment
2. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
3. Ranbaxy gets US FDA approval for Lisinopril
4. Ranbaxy Labs Entry Into Anti-Acne Market
5. Ranbaxy trying to make inroads in herbal drugs market
6. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
7. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
8. Ranbaxy opens Drug discovery centre in Gurgaon
9. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
10. SRL Ranbaxy offers quicker bird flu diagnostic test
11. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... The ... of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and Research (FAER), the ... and the Cigna Foundation, encourages proposals supporting high quality research using perioperative ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and individuals ... have been developed for use by nutrition educators and influencers within the ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to ... the rest of the world with ZANZIBAR MILKY CREAM. Inspired by the beauty of ... like Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, velvety body ...
(Date:1/21/2017)... Boca Raton, FL (PRWEB) , ... January 21, 2017 , ... ... Bump eRaiser, recently attended the January ECRM Trade Show in Hilton Head, SC, where ... an international reputation for the quality of its beauty and wellness products. At this ...
(Date:1/21/2017)... SAINT- MALO, FRANCE (PRWEB) , ... January 21, 2017 , ... ... heart of the Indian Ocean, isolated from the rest of the world with ZANZIBAR ... of East Africa, Phytocéane used key ingredients, Virgin Coconut Oil and moisturizing vegetal coral ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 Ahead of today,s trading session, Stock-Callers.com ... have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ). ... laggards on Friday, January 20 th , 2017, down on the ... on these stocks now at: ...
(Date:1/23/2017)...  ResMed (NYSE : RMD), BMC (Pékin, Chine) et 3B ... qu,ils se sont mis d,accord sur le règlement mondial ... et 3B seront autorisés à vendre leurs produits existants ... ResMed effectuera le paiement de la décision en une ... Floride entre les deux parties. Le règlement n,inclut pas ...
(Date:1/23/2017)... , Jan. 23, 2017 Just two weeks remain until legal ... property, gather in Central London to discuss the ... kind in the market, Parallel Trade 2017 . In ... list of attendees which is available to read in the event ... Some ...
Breaking Medicine Technology: